While most individuals tolerate GLP-1 medications well, potential serious side effects can occur
Research news Mouse experiments have suggested that glucagon-like peptide-1 receptor agonists may reduce pulmonary fibrosis following a COVID-19 infection in people with type 2 diabetes, although researchers cautioned that the findings remain preliminary Glucagon-like peptide-1 (GLP-1) receptor agonists, already used to treat type 2 diabetes (T2DM) and obesity, may also help to reduce the risk of COVID-19-related lung scarring in people with T2DM, according to research in mouse models
In adipocyte models, effects on lipolysis, GLUT4 translocation, and adipokine secretion have been characterised across primary and immortalised cell systems
How many doses are in one vial after mixing
Metformin lowers blood sugar levels and can also help with weight management in some individuals
Pancreatitis Warning Semaglutide may increase the risk of acute pancreatitis, which is short-term inflammation in the pancreas
